Your browser doesn't support javascript.
loading
A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors.
Thomas, Markus; Kienast, Yvonne; Scheuer, Werner; Bähner, Monika; Kaluza, Klaus; Gassner, Christian; Herting, Frank; Brinkmann, Ulrich; Seeber, Stefan; Kavlie, Anita; Welschof, Martin; Ries, Stefan; Weidner, K Michael; Regula, Jörg T; Klein, Christian.
Affiliation
  • Thomas M; Discovery Oncology, Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany. markus.thomas@roche.com
PLoS One ; 8(2): e54923, 2013.
Article in En | MEDLINE | ID: mdl-23405099
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colonic Neoplasms / Angiopoietin-1 / Angiopoietin-2 / Antibodies, Neutralizing / Antineoplastic Agents Type of study: Clinical_trials Limits: Animals / Female / Humans Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2013 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colonic Neoplasms / Angiopoietin-1 / Angiopoietin-2 / Antibodies, Neutralizing / Antineoplastic Agents Type of study: Clinical_trials Limits: Animals / Female / Humans Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2013 Document type: Article Affiliation country: Country of publication: